Oric制药公司今日宣布，其研发的Rinzimetostat（研发代号Oric-944）的临床前研究数据，将于2026年美国癌症研究协会（AACR）年会上进行专题报告。这项突破性研究聚焦于新型小分子抑制剂的抗肿瘤机制，通过靶向表观遗传调控通路展现显著疗效。实验数据表明，该化合物在多种肿瘤模型中能有效抑制癌细胞增殖并诱导凋亡，为后续临床开发奠定坚实基础。此次报告将详细解析其作用机制与潜在治疗价值，引发学界对下一代肿瘤靶向疗法的广泛关注。
Oric制药公司今日宣布，其研发的Rinzimetostat（研发代号Oric-944）的临床前研究数据，将于2026年美国癌症研究协会（AACR）年会上进行专题报告。这项突破性研究聚焦于新型小分子抑制剂的抗肿瘤机制，通过靶向表观遗传调控通路展现显著疗效。实验数据表明，该化合物在多种肿瘤模型中能有效抑制癌细胞增殖并诱导凋亡，为后续临床开发奠定坚实基础。此次报告将详细解析其作用机制与潜在治疗价值，引发学界对下一代肿瘤靶向疗法的广泛关注。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.